Cas:1263287-73-5 (2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde manufacturer & supplier

Chemical Name:(2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde

CAS.NO:1263287-73-5

Synonyms:(2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde

Molecular Formula:C₁₉H₁₅NO₅

Molecular Weight:337.32600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:99.62000

Exact Mass:337.09500

LogP:2.22890

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde Use and application,(2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde technical grade,usp/ep/jp grade.

Related News: Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. (2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? (2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde supplier The Company selected the top-performing clone for generation of the master engineered iPSC bank for GMP production of FT819. (2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde vendor Raw material drug manufacturing is listed as one of the top ten key remediation industries, and it is necessary to implement clean transformation, new construction, reconstruction, and expansion of the ten key remediation industry construction projects to implement equal or reduced emissions of major pollutants; ) The industry implements the green enzyme production technology transformation; at the same time, the ten articles of water classify the industrial discharged sewage, and the sewage discharge of API companies is restricted. (2E)-8-hydroxy-2-[(2E)-2-(3-hydroxy-5-methoxy-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1H-quinoline-7-carbaldehyde factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.